Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biogen Idec
(NQ:
BIIB
)
200.81
-0.99 (-0.49%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Biogen Idec
< Previous
1
2
...
27
28
29
30
31
32
33
34
35
...
39
40
Next >
Where Biogen Stands With Analysts
October 12, 2021
Within the last quarter, Biogen (NASDAQ:BIIB) has observed the following a...
Via
Benzinga
Why Humana Is Suing Biogen
October 09, 2021
Biogen continues to deal with the aftermath of allegedly paying co-pays for some Medicare patients.
Via
The Motley Fool
Analyst Ratings For Biogen
October 08, 2021
Over the past 3 months, 10 analysts have published their opinion on Biogen (NASDAQ:
Via
Benzinga
Could Biogen's Blockbuster Hopes for Alzheimer's Disease Drug Aduhelm Be Doomed?
October 08, 2021
Aduhelm could face yet another hurdle with reports of safety issues.
Via
The Motley Fool
3 Biotech Stocks That Could Make You Richer in October and Beyond
October 07, 2021
Three Motley Fool contributors think these biotech stocks should be big winners.
Via
The Motley Fool
Analyst Ratings For Biogen
September 29, 2021
Biogen (NASDAQ:BIIB) has observed the following analyst ratings within the...
Via
Benzinga
Where Biogen Stands With Analysts
September 23, 2021
Within the last quarter, Biogen (NASDAQ:BIIB) has observed the following a...
Via
Benzinga
Expert Ratings For Biogen
September 16, 2021
Over the past 3 months, 7 analysts have published their opinion on Biogen (NASDAQ:
Via
Benzinga
Portfolio Review: Biogen & T. Rowe Price
September 12, 2021
Biogen reported second quarter sales declined 25% to $2.8 billion. T. Rowe Price reported strong second quarter results with revenues rising 36% to $1.9 billion.
Via
Talk Markets
Merck Keeps M&A Mode On With Mirati, Biogen, mRNA Companies On Radar: FT
October 06, 2021
Merck & Co Inc (NYSE: MRK) remains in a deal-hunting mode despite its recent $11.5 billion acquisition of Acceleron. Related: Merck Seals Acceleron Pharma Deal...
Via
Benzinga
Rising Oil Prices and Yields Makes Market Navigation More Complex
October 05, 2021
Bitcoin (/BTC) topped $50,000 this morning for the first since May, but traders may be more focused on oil prices and yields. Crude oil (/CL) is continuing its rise...
Via
Benzinga
Exposures
Fossil Fuels
See Why Perrigo Shares Are Moving Higher On Thursday
September 30, 2021
Over-the-counter drugs company Perrigo Company plc (NYSE:
Via
Benzinga
A Bit Of A Recovery
September 29, 2021
While Germany remains without a government, Japan has a new prime minister who will lead his party in the election this week.
Via
Talk Markets
Eisai, Biogen Initiate Rolling Submission For New Alzheimer's Drug
September 28, 2021
Eisai Co Ltd (OTC: ESALY) began its application process for lecanemab (BAN2401) for early Alzheimer's disease using an accelerated approval pathway. Lecanemab...
Via
Benzinga
The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
September 28, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27) Acceleron Pharma Inc. (...
Via
Benzinga
Benzinga's Bulls And Bears Of The Week: Apple, Bitcoin, Disney, Microsoft And More
September 25, 2021
Benzinga has examined the prospects for many investor favorite sto...
Via
Benzinga
Aduhelm's 'Blockbuster Potential' Is Underappreciated, Says Biogen Analyst
September 23, 2021
It's been about four months since Biogen, Inc. (NASDAQ:BII...
Via
Benzinga
Biogen Stock Pops, But D.C. Center Bans All — Not Just Aduhelm — Sales Reps
September 23, 2021
Biogen stock rose on a buy rating even as the Aduhelm controversy deepened.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021
September 23, 2021
Upgrades Barclays upgraded the previous rating for Warner Music Group Corp (NASDAQ:
Via
Benzinga
Thinking About Buying Stock Or Options In Tesla, Ballard Power, Bloom Energy Or Biogen?
September 23, 2021
One of the most common questions traders have about stocks is “Why Is It Moving?” That’s why Benzinga created the Why Is It Moving, or WIIM, feature in...
Via
Benzinga
Apple Working On iPhone Features To Detect Depression, Cognitive Decline: Report
September 21, 2021
Apple, Inc. (NASDAQ: AAPL) is reportedly nurturing serious ambitions to expand its presence in the health care sector. What Happened: Apple is working on deploying its...
Via
Benzinga
The Cassava Saga: Here's What You Need To Know About This Embattled Alzheimer's Stock
September 21, 2021
Cassava Sciences could hold the holy grail in Alzheimer's treatment. But once highflying SAVA stock has plummeted in a firestorm this year.
Via
Investor's Business Daily
Biogen Reports Mixed Phase 2 Data For Its Non-Opioid Pain Candidate
September 16, 2021
Biogen Inc (NASDAQ: BIIB) has announced topline results from its Phase 2 CONVEY study of vixotrigine (BIIB074) for small fiber neuropathy (SFN). SFN is a disorder...
Via
Benzinga
Biogen Launches High-Dose Spinraza Trial In Evrysdi Treated Patients: What You Need To Know
September 15, 2021
Biogen Inc's (NASDAQ: BIIB) Spinraza (nusinersen), spinal muscular atrophy (SMA) drug launched in early 2017, faces new competition from Roche Holdings AG's...
Via
Benzinga
The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold
September 17, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Bicycle Therapeutics plc (...
Via
Benzinga
The Week Ahead In Biotech (Sept. 12-18): Calliditas FDA Decision, Adcom Review For Pfizer/BioNTech COVID-19 Vaccine, Oncology Conference And IPOs
September 12, 2021
Biotech stocks retreated in the holiday-shortened week ending Sept. 10, reversing course from the previous week. Humanigen, Inc. (NASDAQ: HGEN) was among the biggest...
Via
Benzinga
Exposures
COVID-19
Product Safety
Why Biogen Stock Is Sinking This Week
September 10, 2021
The U.S. launch of Alzheimer's disease drug Aduhelm is off to a sluggish start.
Via
The Motley Fool
Why Biogen Shares Are Falling
September 09, 2021
Biogen Inc (NASDAQ: BIIB) shares are trading lower by 7% at $298.83 following reports the company's CEO highlighted a slower-than-anticipated launch of Aduhelm. Biogen...
Via
Benzinga
Biogen Stock Dives As CEO Admits 'Slower Than We Anticipated' Alzheimer's Drug Launch
September 09, 2021
Biogen stock tumbled Thursday after its CEO admitted the launch of Alzheimer's drug Aduhelm has been "slower than we anticipated."
Via
Investor's Business Daily
Why Biogen Stock Is Slipping Today
September 09, 2021
Aduhelm's commercial launch isn't off to a strong start.
Via
The Motley Fool
< Previous
1
2
...
27
28
29
30
31
32
33
34
35
...
39
40
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.